Digestive Care Inc., of Bethlehem, PA, and its marketing partner, Chiesi USA Inc., of Cary, NC, said the FDA approved a labeling revision to include gastrostomy tube administration of the 4,000 USP lipase units capsule of Pertzye (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.